123524-52-7 Azelnidipine AKSci G790
 
 
Loading Please Wait...
  G790    
Azelnidipine
, 98% (HPLC)
 
2-Amino-1,4-dihydro-6-methyl-4-(3 nitrophenyl)-3,5-pyridinedicarboxylic acid 3-[1-(diphenylmethyl)-3-azetidinyl] 5-(1-methylethyl) ester




IDENTITY
CAS Number:123524-52-7
MDL Number:MFCD00865803
MF:C33H34N4O6
MW:582.65
SPECIFICATIONS & PROPERTIES
Purity:98% (HPLC)
Physical Form:Yellow powder
Melting Point:193-200°C
Long-Term Storage:Store at room temperature
UN #:Not hazmat

BIOLOGICAL INFO
Solubility:DMSO: >10 mg/mL
Application(s):Dihydropyridine calcium channel blocker

REVIEW

 Azelnidipine is a dihydropyridine calcium channel blocker with selectivity for L-type calcium channels that is approved in Japan for the treatment of patients with hypertension. It has a gradual onset and has a long-lasting hypotensive effect, with little increase in heart rate. Azelnidipine is approved for use in treating ischemic heart disease and cardiac remodeling after myocardial infarction. Azelnidipine has also been shown to have antioxidant effects in endothelial cells and cardiomyocytes.

REFERENCES
[1]Kobayashi, Takashi; Inoue, Teruhiko; Nishino, Shigeyoshi; Fujihara, Yoshimi; Oizumi, Kiyoshi; Kimura, Tomio Chemical & Pharmaceutical Bulletin (1995), 43(5), 797-817.
[2] Yoshida, Hiroshi; Miyata, Hiroyuki; Inoue, Teruhiko; Furubayashi, Takashi; Nishino, Shigeyoshi Preparation of antihypertensive dihydropyridine derivative Jpn. Kokai Tokkyo Koho (1999), JP 11116570 A 19990427.
[3] Oizumi K, Nishino H, Koike H, Sada T, Miyamoto M, Kimura, Antihypertensive effects of CS-905, a novel dihydropyridine Ca++ channel blocker, Jpn. J. Pharmacol. 1989, 51 (1): 57-64.
[4] Arita M, Hashizume T, Tanigawa K, Yamamoto H, Nishio I. A new Ca-antagonist, azelnidipine, reduced blood pressure during exercise without augmentation of sympathetic nervous system in essential hypertension: a randomized, double-blind, placebo-controlled trial. J Cardiovasc Pharmacol. 1999 Feb;33(2):186-92.

GHS

Pictograms

Signal Word
Danger

Hazard Statements
H302; H318

Precautionary Statements
P264; P270; P280; P301+P312; P305+P351+P338; P310; P330; P501


Current as of January 18, 2019


Download SDS

CATEGORIES

 APIs and Bioactives > Calcium Channel Blockers


PubChem
  @PubMed